

D.A.Putilin
A.M.Kamyshny

Zaporizhzhia State
Medical University

Key words:

experimental streptozotocin-induced diabetes mellitus, pancreatic lymph nodes, Glut1, mTOR, AMPK1 α .

Received: 24.04.2016
Accepted: 15.05.2016

UDC 616.428:616.37]-008.953.2:[616.379-008.64+616.379-008.64-085.252. 349.7]-092.9

FEATURES OF IMMUNE METABOLISM OF LYMPHOCYTES IN PANCREATIC LYMPH NODES DURING EXPERIMENTAL STEPTOZOTOCIN-INDUCED DIABETES MELLITUS AND AFTER INTRODUCTION OF METFORMIN

ABSTRACT. Background. Metabolic changes in terms of developing diabetes, especially hyperglycemia, can directly affect immune metabolism of lymphocytes. **Objective:** The aim was to find out the level of mRNA gene expression of *Glut1*, *mTOR* and *AMPK1 α* in pancreatic lymphatic nodes (PLN) in rats with experimental streptozotocin-induced diabetes mellitus (ESIDM) and after introduction of metformin. **Methods.** *Glut1*, *mTOR* and *AMPK1 α* mRNA expression were analyzed by real-time reverse transcriptase-polymerase chain reaction. Total RNA was extracted from PLN tissue by Trizol RNA Prep 100 (Isogen, Russia), according to the manufacturer's instructions. RNA was re-suspended in RNase free water, quantified and subjected to RT-PCR reaction using RT-PCR kit; RT (Syntol, Russia). To determine the level of *Glut1*, *mTOR* and *AMPK1 α* mRNA, RT-PCR was performed in real-time by thermal cycler CFX96™ Real-Time PCR Detection Systems (Bio-Rad Laboratories, Inc., USA). The relative level of gene expression were studied with rat reference genes GAPDH by the method $\Delta\Delta C_t$. Statistical analysis were conducted using available software «Bio-Rad SFX Manager 3.1» (Bio-Rad, USA). **Results.** It was established that hyperglycemia caused the transcript induction of genes of glucose transporter *Glut1* (in 9,9-28,9 times, $p < 0,05$) and protein kinase *mTOR* (in 5.3-3.3 times, $p < 0.05$) in cells of PLN. Introduction of metformin to the diabetic rats resulted in an increased level of mRNA gene of *AMPK1 α* by 87% ($p < 0.05$) on the 3rd week and 38 fold ($p < 0.05$) on the 5th week of ESIDM development and inhibition of *mTOR* expression in PLN (in 3-14.7 times, $p < 0.05$). Revealed increase of *Glut1* and *mTOR* mRNA genes level in the PLN cells during diabetes can trigger their differentiation in effective pro-inflammatory subpopulation of Th1- and Th17-lymphocytes. **Conclusion.** Increased level of *AMPK1 α* mRNA and inhibition of *mTOR* expression in PLN after *metformin* introduction to diabetic rats gives evidence about the possibility for correction of immune violations that develop during diabetes.

© D.A.Putilin, A.M.Kamyshny, 2016
✉ des.doctor@mail.ru; alexkamyshny@yandex.ru

Citation:

Putilin DA, Kamyshny AM. Features of immune metabolism of lymphocytes in pancreatic lymph nodes during experimental streptozotocin-induced diabetes mellitus and after introduction of metformin. Morphologia. 2016;10(2):61-8. Ukrainian.







Fig. 1. Relative normalized number of genes *GLUT1* (A) and *mTOR* (C) mRNA with their amplification graphs (B, D) in the pancreatic lymph node cells. Normalization according to the method of $\Delta\Delta C_t$ with reference gene *GAPDH*. c-control; d3, d5 – 3 weeks and 5 weeks of experimental streptozotocin-induced diabetes mellitus respectively.




Fig. 2. Relative normalized number of genes *AMPK1α* (A,B) and *mTOR* (C, D) mRNA in the pancreatic lymph node cells after metformin introduction to diabetic rats. Normalization according to the method of $\Delta\Delta C_t$ with reference gene *GAPDH*. c-control; d3, d5 – 3 weeks and 5 weeks of experimental streptozotocin-induced diabetes mellitus respectively.




Fig. 3. Immune metabolism of lymphocytes in diabetes mellitus.

References

1. Calderon B, Unanue E. Antigen presentation events in autoimmune diabetes. *Curr Opin Immunol.* 2012; 24(1): 119-28.
2. Gagnerault M, Luan J, Lotton C, Lepault F. Pancreatic lymph nodes are required for priming of β cell reactive T cells in NOD mice. *J Exp Med.* 2002; 196:369-77.
3. Buck MD, O'Sullivan D, Pearce EL. T cell metabolism drives immunity. *J Exp Med.* 2015; 24;212(9):1345-60.
4. Palmer CS, Hussain T, Duette G, Weller TJ, Ostrowski M, Sada-Ovalle I, Crowe SM. Regulators of glucose metabolism in CD4⁺ and CD8⁺ T cells. *Int Rev Immunol.* 2015; 25:1-12.
5. Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D, Anderson SM, Abel ED, Chen BJ, Hale LP, Rathmell JC. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. *Cell Metab.* 2014; 1;20(1):61-72.
6. Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, Sullivan SA, Nichols AG, Rathmell JC. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4⁺ T cell subsets. *J Immunol.* 2011; 15;186(6):3299-303.
7. Basu S, Hubbard B, Shevach EM. Foxp3-mediated inhibition of Akt inhibits Glut1 (glucose transporter 1) expression in human T regulatory cells. *J Leukoc Biol.* 2015; 97(2):279-83.
8. Pollizzi KN, Patel CH, Sun IH, Oh MH, Waickman AT, Wen J, Delgoffe GM, Powell JD. mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation. *J Clin Invest.* 2015; 125(5):2090-108.
9. Pollizzi KN, Powell JD. Regulation of T cells by mTOR: the known knowns and the known unknowns. *Trends Immunol.* 2015; 36(1):13-20.
10. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. *Cell Metab.* 2014; 2;20(6):953-66.
11. Hardie DG, Ashford ML. AMPK: regulating energy balance at the cellular and whole body levels. *Physiology (Bethesda).* 2014;29(2):99-107.
12. Shan J, Feng L, Sun G, Chen P, Zhou Y, Xia M, Li H, Li Y. Interplay between mTOR and STAT5 signaling modulates the balance between regulatory and effective T cells. *Immunobiology.* 2015;220(4):510-7.

13. Liu Y, Zhang DT, Liu XG. mTOR signaling in T cell immunity and autoimmunity. *Int Rev Immunol.* 2015;34(1):50-66.
14. Chapman NM, Chi H. mTOR signaling, Tregs and immune modulation. *Immunotherapy.* 2014;6(12):1295-311.
15. Zeng H, Chi H. Metabolic control of regulatory T cell development and function. *Trends Immunol.* 2015; 36(1):3-12.
16. Gerriets V, Rathmell J. Metabolic pathways in T cell fate and function. *Trends Immunol.* 2012; 33(4):168–73.
17. Xu X, Ye L, Araki K, Ahmed R. mTOR, linking metabolism and immunity. *Semin Immunol.* 2012; 24(6):429-35.
18. Yang K, Chi H. mTOR and metabolic pathways in T cell quiescence and functional activation. *J Semin Immunol.* 2012;421:8.
19. Waickman AT, Powell JD. mTOR, metabolism, and the regulation of T-cell differentiation and function. *J Immunol Rev.* 2012; 43-58.
20. Chi H. Regulation and function of mTOR-signalling in T cell fate decisions. *J Nat Rev Immunol.* 2012; 325:38.
21. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. *Annu Rev Immunol.* 2012; 39-68.
22. Russo GL, Russo M, Ungaro P. AMP-activated protein kinase: a target for old drugs against diabetes and cancer. *J Biochem Pharmacol.* 2013;339:50.
23. Hardie D. AMPK: a target for drugs and natural products with effects on both diabetes and cancer. *J Diabetes.* 2013;62(216):72.
24. Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, McCormick L L, Fitzgerald P, Chi H, Munger J, Green DR. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. *Immunity.* 2011;35:871-82.
25. Zarrouk M, Finlay DK, Foretz M, Viollet B, Cantrell DA. Adenosine-mono-phosphate-activated protein kinase independent effects of metformin in T cells. *PLoS One.* 2014;9(9):e106710.
26. Rolf J, Zarrouk M, Finlay DK, Foretz M, Viollet B. AMPK α 1: A glucose sensor that controls CD8 T-cell memory. *Eur J Immunol.* 2013;43(4):889-96.
27. Kang KY, Kim Y-K, Yi H, Kim J, Jung H-R. Metformin down regulates Th17 cells differentiation and attenuates murine autoimmune arthritis. *International Immunopharmacology;* 2013;16(1):85-92.

28. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. *Nature*.2009;460:103-7.
29. Nath N, Khan M, Paintlia MK, Hoda MN, Giri S. Metformin Attenuated the Autoimmune Disease of the Central Nervous System in Animal Models of Multiple Sclerosis. *The Journal of Immunology*. 2009;182:8005-14.
30. Green AS, Chapuis N, TrovatiMaciel T, Willems L, Lambert M, et al. The LKB1/AMPK signal in gpath way has tumor suppress or activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenicm RNA translation. *Blood*.2010;116:4262-73.
31. Dworacki G, Urazayev O, Bekmukhambetov Y, Iskakova S, Frycz BA, Jagodziński PP, Dworacka M. Thymic emigration patterns in patients with type 2 diabetes treated with metformin. *Immunology*. 2015;146(3):456-69.
32. Yin Y, Choi SC, Xu Z, Zeumer L, Kanda N, Croker BP, Morel L. Glucose Oxidation Is Critical for CD4+ T Cell Activation in a Mouse Model of Systemic Lupus Erythematosus. *J Immunol*. 2015;pii: 1501537.
33. Shin S, Hyun B, Lee A, Kong H, Han S, Lee CK, Ha NJ, Kim K. Metformin Suppresses MHC-Restricted Antigen Presentation by Inhibiting Co-Stimulatory Factors and MHC Moleculesin APCs. *Biomol Ther*. 2013;21(1):35-41.
34. Forslund K, Hildebrand F, Nielsen T et al. Disentanglingtype 2 diabetes and metformin treatments ignatures in the human gut microbiota. *Nature*. 2015;528(7581):262-6.